他拉泊芬钠(Talaporfin Sodium) - 在研适应症：食管癌，脑癌，肺癌_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Aptocine、Leserfin、Litx

+ [14]

靶点-

作用机制

光敏剂

治疗领域

肿瘤神经系统疾病消化系统疾病+ [1]

在研适应症

食管癌脑癌肺癌

非在研适应症

乳腺癌心血管疾病脉络膜新生血管+ [17]

原研机构

Meiji Seika Pharma Co., Ltd.

在研机构

Meiji Seika Pharma Co., Ltd.

非在研机构

Light Sciences Oncology, Inc.Light Sciences, Inc.

最高研发阶段批准上市

首次获批日期

日本 (2003-10-16),

肺癌

最高研发阶段(中国)-

特殊审评孤儿药 (日本)

登录后查看时间轴

结构/序列

分子式C38H41N5Na4O9

InChIKeyDSZWCAQEOJGGCM-LBARBQQXSA-N

CAS号220201-34-3

查看全部结构式(2)

关联

26

项与他拉泊芬钠相关的临床试验

JPRN-jRCTs041230002

/ Suspended临床2/3期IIT

Specified clinical study of the effects of photodynamic therapy using ME2906 and PNL6405CIN for patients with cervical intraepithlial neoplasia on vaginal bacteria

开始日期2023-04-05

申办/合作机构-

JPRN-jRCT2041220118

/ Recruiting临床1/2期IIT

Phase1/2 study of endoscopic photodynamic therapy using ME2906 and ultrathin PDT probe in unresectable bile duct cancer

开始日期2023-02-03

申办/合作机构-

JPRN-jRCT2021220040

/ Recruiting临床2期IIT

Multi-institutional phase II study of photodynamic therapy using ME2906 and PNL6405SCT for patients with malignant spinal cord tumor.

开始日期2023-01-12

申办/合作机构-

100 项与他拉泊芬钠相关的临床结果

登录后查看更多信息

100 项与他拉泊芬钠相关的转化医学

登录后查看更多信息

100 项与他拉泊芬钠相关的专利（医药）

登录后查看更多信息

271

项与他拉泊芬钠相关的文献（医药）

2024-10-21·ACS Applied Bio Materials

Water-Soluble Rotaxane-Type Porphyrin Dyes as a Highly Membrane-Permeable and Durable Photosensitizer Suitable for Photodynamic Therapy

Article

作者: Iwamura, Munetaka ; Chiba, Junya ; Ohishi, Yuki ; Yamashita, Juri ; Nozaki, Koichi ; Zhou, Yue ; Ichikawa, Taiki ; Yokoyama, Satoru ; Inouye, Masahiko

Porphyrins have emerged as highly effective photosensitizers in the field of photodynamic therapy (PDT) because of their high singlet oxygen generation efficiency. However, most porphyrin derivatives do not have adequate water solubility and cell membrane permeability suitable for use in PDT. In addition, they frequently suffer from low durability under photoirradiation. Here, we propose rotaxane-type photosensitizers, in which a porphyrin axle is irreversibly encapsulated within cyclodextrins (CDs), to overcome the drawbacks of porphyrins for PDT. The rotaxane-type photosensitizers were synthesized in high yields by employing a cooperative capture strategy. The CD derivatives worked as a transparent shell to impart a porphyrin axle not only with water solubility but also with photostability. These rotaxanes showed higher cell membrane permeability and photoinduced cytotoxic abilities than talaporfin sodium, presently used as a clinical photosensitizer. The rotaxane-based photosensitizer could have potential for being ideal PDT drugs.

2024-10-01·World Neurosurgery

The Safety of Intraoperative Photodynamic Diagnosis Using 5-Aminolevulinic Acid Combined with Talaporfin Sodium Photodynamic Therapy in Recurrent High-Grade Glioma

Article

作者: Miki, Shunichiro ; Matsuda, Masahide ; Kohzuki, Hidehiro ; Tsurubuchi, Takao ; Ishikawa, Eiichi ; Sugii, Narushi ; Zaboronok, Alexander

BACKGROUNDIntraoperative photodynamic diagnosis (PDD) using 5-aminolevulinic acid (5-ALA) is a widely adopted technique to enhance the extent of resection during high-grade glioma (HGG) surgery. Recent updates to the package insert for 5-ALA in Japan now allow its use in combination with drugs that may induce photosensitivity, such as talaporfin sodium (TS). TS is employed in intraoperative photodynamic therapy (PDT) and has been shown to improve overall survival. The combination of 5-ALA with TS is expected to offer further benefits. However, the safety of this combination had not been established. This study reports on the safety of 5-ALA-PDD with TS-PDT in the treatment of recurrent HGG.METHODS7 patients with recurrent HGG underwent tumor resection using a combination of 5-ALA-PDD and TS-PDT. The incidence of photosensitivity as an adverse effect associated with 5-ALA and TS was evaluated as described in the package insert. Adverse events were assessed according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.RESULTSTumor-specific fluorescence intensity was strong in 4 cases and weak in 3. Photosensitivity occurred in only 1 patient (14.3%). Three patients exhibited CTCAE grade 1 or 2 abnormal liver function, and 1 patient experienced CTCAE grade 1 γ-GTP elevation. All abnormalities improved during follow-up.CONCLUSIONSThe combined use of 5-ALA-PDD and TS-PDT for HGG surgery did not increase the risk of serious adverse events in our study. Further investigations with a larger number of cases are needed for a more accurate assessment of its safety and efficacy.

2024-07-01·Biomedicine & Pharmacotherapy

Repurposing anti-cancer porphyrin derivative drugs to target SARS-CoV-2 envelope

Article

作者: Schaberle, Fabio A ; Cadima-Couto, Iris ; Arnaut, Luis G ; Castanho, Miguel A R B ; Arnaut, Zoe A ; Buga, Carolina C ; Mendonça, Diogo A ; Cruz-Oliveira, Christine

Antiviral medicines to treat COVID-19 are still scarce. Porphyrins and porphyrin derivatives (PDs) usually present broad-spectrum antiviral activity with low risk of resistance development. In fact, some PDs are clinically approved to be used in anti-cancer photodynamic therapy and repurposing clinically approved PDs might be an alternative to treat COVID-19. Here, we characterize the ability of temoporfin, verteporfin, talaporfin and redaporfin to inactivate SARS-CoV-2 infectious particles. PDs light-dependent and -independent effect on SARS-CoV-2 infectivity were evaluated. PDs photoactivation successfully inactivated SARS-CoV-2 with very low concentrations and light dose. However, only temoporfin and verteporfin inactivated SARS-CoV-2 in the dark, being verteporfin the most effective. PDs treatment reduced viral load in infected Caco-2 cells, while not inducing cytotoxicity. Furthermore, light-independent treatment with temoporfin and verteporfin act on early stages of viral infection. Using lipid vehicles as membrane models, we characterized PDs interaction to the viral envelope. Verteporfin presented the lowest IC50 for viral inactivation and the highest partition coefficients (K_p) towards lipid bilayers. Curiously, although temoporfin and redaporfin presented similar K_ps, redaporfin did not present light-independent antiviral activity, and only temoporfin and verteporfin caused lipid membrane disorder. In fact, redaporfin is located closer to the bilayer surface, while temoporfin and verteporfin are located closer to the centre. Our results suggest that viral envelope affinity, with penetration and destabilization of the lipid bilayer, seems critical to mediate PDs antiviral activity. Altogether, these findings open new avenues for the off-label application of temoporfin and verteporfin in the systemic treatment of COVID-19.

100 项与他拉泊芬钠相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D01985	他拉泊芬钠	L01	DB11812

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
食管癌	日本	Meiji Seika Pharma Co., Ltd.	2015-05-20
脑癌	日本	Meiji Seika Pharma Co., Ltd.	2013-09-20
肺癌	日本	Meiji Seika Pharma Co., Ltd.	2003-10-16

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
不可切除的肝细胞癌	药物发现	克罗地亚	Light Sciences Oncology, Inc.	2006-07-01
不可切除的肝细胞癌	药物发现	韩国	Light Sciences Oncology, Inc.	2006-07-01
不可切除的肝细胞癌	药物发现	印度	Light Sciences Oncology, Inc.	2006-07-01
不可切除的肝细胞癌	药物发现	菲律宾	Light Sciences Oncology, Inc.	2006-07-01
不可切除的肝细胞癌	药物发现	马来西亚	Light Sciences Oncology, Inc.	2006-07-01
不可切除的肝细胞癌	药物发现	塞尔维亚	Light Sciences Oncology, Inc.	2006-07-01
不可切除的肝细胞癌	药物发现	新加坡	Light Sciences Oncology, Inc.	2006-07-01
不可切除的肝细胞癌	药物发现	泰国	Light Sciences Oncology, Inc.	2006-07-01
不可切除的肝细胞癌	药物发现	中国香港	Light Sciences Oncology, Inc.	2006-07-01
不可切除的肝细胞癌	药物发现	波兰	Light Sciences Oncology, Inc.	2006-07-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


UEGW2024	N/A	肿瘤	-	Talaporfin PDT	窪鹽膚襯艱鏇網構選淵(觸齋築簾願鬱醖憲選積) = 鏇構構壓憲觸選鹽網廠範構範觸積鏇鬱醖廠選 (鹽餘襯鹹網遞構夢觸願 ) 更多	-	2024-10-13
				Talaporfin (STING knockout cells)	窪鹽膚襯艱鏇網構選淵(觸齋築簾願鬱醖憲選積) = 廠鹽鑰觸襯積襯艱壓蓋範構範觸積鏇鬱醖廠選 (鹽餘襯鹹網遞構夢觸願 ) 更多
P11.10.B (EANO2023)	N/A	胶质母细胞瘤 IDH mutant \| MGMT promotor methylation	145	PDT with Talaporfin Sodium	膚製憲襯鹽醖遞構選壓(願鬱壓獵遞繭積鹹繭鑰) = 1 case in PDT group 壓夢壓窪鏇蓋鹽鹽壓築 (獵積遞蓋積窪範窪築夢 ) 更多	积极	2023-09-08
				Talaporfin sodium (Non-PDT Group)
SURG-27 (SNO2022)	N/A	复发性胶质母细胞瘤	-	Talaporfin sodium mediated photodynamic therapy (PDT)	醖夢膚鹹窪窪築觸觸憲(襯膚願網繭醖餘獵築憲) = no case did treatment-related severe adverse effects 鏇選鬱簾膚襯鬱製積鹽 (鹹醖鬱網鹽構膚艱簾簾 )	积极	2022-11-14
				Talaporfin sodium (Maximal resection alone)
UEGW2019	N/A	食管癌	-	Talaporfin sodium	顧醖淵鹹遞淵憲製繭淵(糧築憲餘鹹選選憲鑰鹹) = 積獵鬱憲鹹選膚築構選蓋選蓋鏇糧餘積築糧鹽 (築鹽積鬱範糧繭壓鹹憲 )	-	2019-10-01
ACTR-39 (SNO2016)	临床2期	胶质母细胞瘤	-	PDT with Talaporfin sodium and semiconductor laser	網醖鬱遞夢淵鏇齋構觸(鬱積獵醖淵觸簾壓鹽簾) = 簾遞襯窪選網艱壓願餘蓋廠鬱網廠積簾憲膚觸 (憲齋襯積醖鑰憲衊觸蓋 ) 更多	积极	2016-11-07
				Talaporfin sodium (Surgical resection)	(齋積廠製鏇顧願積壓醖) = 淵艱顧膚範繭艱範夢鹹獵繭蓋壓構積觸夢築繭 (餘艱積願膚壓淵齋鹹憲 ) 更多
NCT00440310 (CTgov)	临床3期	肝转移 \| 结直肠癌 \| 局部肿瘤复发	483	Interstitial light emitting diodes+leucovorin+irrinotecan+oxaliplatin+fluorouracil+Talaporfin sodium (Litx + Chemotherapy)	(糧繭鹽鹹膚觸觸網餘壓) = 簾衊繭糧選鏇鏇遞壓簾鏇積鬱憲構餘簾壓窪衊 (鏇網鹹鏇糧鹽簾壓糧廠, 鏇憲蓋鹽網鏇構襯鏇獵 ~ 糧構膚積膚窪製齋鬱淵) 更多	-	2015-08-25
				leucovorin+irrinotecan+oxaliplatin+fluorouracil (Chemotherapy Alone)	(糧繭鹽鹹膚觸觸網餘壓) = 餘鬱願簾鏇壓鹹齋範憲鏇積鬱憲構餘簾壓窪衊 (鏇網鹹鏇糧鹽簾壓糧廠, 鹹繭醖衊積窪艱膚顧顧 ~ 構窪餘鑰鏇製積糧製選) 更多
JPRN-UMIN000003970 (ASCO_GI2012)	临床1期	复发性食管鳞状细胞癌 \| 食管癌	9	Talaporfin sodium-based PDT	(淵鹽艱淵憲廠艱獵遞鏇) = 範餘構築範獵壓築鹽繭構鬱鹹願餘壓繭衊鬱齋 (積遞遞淵憲鹹鏇鑰襯簾 )	-	2012-02-01
ASCO2006	N/A	肺癌	204	Laserphyrin	(簾夢襯襯齋夢簾顧簾網) = 顧鹽積膚蓋製醖糧鬱鑰淵鹹築廠範艱鑰艱窪艱 (網蓋糧繭簾製願構製選 )	-	2006-06-20
ASCO2005	临床2期	结直肠癌肝转移	10	Talaporfin sodium + intratumoral placement of LEDs	糧遞鑰鬱淵醖憲顧網鬱(齋築範淵夢廠鑰積製淵) = 鏇衊選鏇鑰廠壓艱糧範窪範選餘鏇積網鏇壓繭 (膚壓鹽廠艱願範窪窪齋 )	-	2005-06-01